Modality
ADC
MOA
CFTRmod
Target
TYK2
Pathway
DDR
NBSCLCAS
Development Pipeline
Preclinical
~Feb 2021
→ ~May 2022
Phase 1
~Aug 2022
→ ~Nov 2023
Phase 2
Feb 2024
→ Jan 2025
Phase 2Current
NCT05738853
2,864 pts·AS
2024-02→2025-01·Completed
NCT07618850
754 pts·NB
2025-04→TBD·Recruiting
3,618 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-01-101.2y agoPh2 Data· AS
Trial Timeline
Q2Q3Q42025Q2
P2
Complet…
P2
Recruit…
Catalysts
Ph2 Data
2025-01-10 · 1.2y ago
AS
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05738853 | Phase 2 | AS | Completed | 2864 | Biomarker |
| NCT07618850 | Phase 2 | NB | Recruiting | 754 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 | |
| COR-9566 | Corcept | Approved | TYK2 | |
| Talazasiran | Kymera | NDA/BLA | MET | |
| DAW-8159 | Day One Bio | Phase 2 | PSMA |